Expert Interview
A Third look: Discussing the current standard of care and the potential of VLA15, a multivalent recombinant protein vaccine candidate that targets six serotypes of Borrelia currently in development by Valneva and Pfizer.
Ticker(s): VALN, PFEInstitution: Lakeshore ID Associates
- Chief of Infectious Diseases and Head of Infection Control at Amita Saint Joseph Hospital in Chicago, and a partner at Lakeshore Infectious Disease Associate
- Infectious Disease specialist since 1997 with extensive clinical experience and currently treats 250 patients with HIV.
- Particular areas of clinical interest include, bacterial infections (MRSA and others), tuberculosis, Clostridium difficile infections, viral infections, wounds and skin, bone and joint infections.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
